Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066846 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00066846: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00066846 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00066846, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Bevacizumab may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as fluorouracil and leucovorin use different ways to stop tumor cells from dividing so they stop growing or die. Combining bevacizumab with fluorouracil and leucovorin may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining bevacizumab with fluorouracil and leucovorin in treating patients who have locally advanced or metastatic stage IV colorectal cancer that has progressed after standard chemotherapy.
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- BIOLOGICAL bevacizumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-08 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00066846
The ClinicalTrials.gov registry entry for NCT00066846 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which fluorouracil is the first listed.
NCT00066846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00066846 about?
NCT00066846 is a clinical study titled "Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy". RATIONALE: Bevacizumab may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as fluorouracil and leucovorin use different ways to stop tumor cells from dividing so they stop growing or die. Combining bevacizumab with fluorouracil...
What is the current status of trial NCT00066846?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-08. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00066846?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00066846?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.